WIP1 inhibition as a new therapeutic strategy for collapsing glomerulopathy

Shreeram Akilesh1

  • 1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.

Kidney International
|April 20, 2024
PubMed

Insights

Researchers identified WIP1 phosphatase as a novel therapeutic target for collapsing glomerulopathy (CG), an aggressive kidney disease. Blocking WIP1 activity showed protective effects in mouse models, offering hope for new CG treatments.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pathology

Background:

  • Collapsing glomerulopathy (CG) is a severe form of focal and segmental glomerulosclerosis.
  • Identifying novel therapeutic targets is crucial for managing CG progression.

Purpose of the Study:

  • To investigate WIP1 phosphatase as a potential therapeutic target for collapsing glomerulopathy.
  • To evaluate the efficacy of targeting WIP1 in preclinical models of CG.

Main Methods:

  • Genetic ablation of WIP1 in mouse models of CG.
  • Pharmacologic inhibition of WIP1 activity.
  • Assessment of kidney pathology and function in treated mice.

Main Results:

  • Blockade of WIP1 activity demonstrated protective effects in two distinct mouse models of CG.
  • This suggests WIP1 plays a critical role in the pathogenesis of CG.

Conclusions:

  • WIP1 phosphatase represents a promising therapeutic target for collapsing glomerulopathy.
  • Targeting WIP1 offers a potential strategy for developing novel treatments for this aggressive kidney disease.

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
440
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
170
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
613